Ocumetics wins ethics OK for human lens implant trial

Executive Summary

• Ocumetics Technology Corp. has received verbal ethics committee approval for the first-in-human clinical study of its accommodating intraocular lens (IOL) at a clinical site in Mexico City.
• Formal written approval for the study protocol is expected by August 5, 2025.
• The approval allows Ocumetics to proceed with patient recruitment and prepare for the first human implantation of the lens, marking a significant milestone in the company's 18-year development journey.

Key Details

• Approval Status: Verbal ethics committee approval received for the first-in-human study protocol.
• Location: Clinical site in Mexico City.
• Product: Ocumetics accommodating intraocular lens, designed to fit within the natural lens compartment and allow the eye's natural muscle activity to shift focus from distance to near, potentially eliminating the need for glasses or contact lenses.
• Next Steps: Formal written approval expected by Aug. 5, 2025; patient recruitment to begin in preparation for the first human implantation.
• Protocol Scope: The approved protocol outlines clinical procedures, safety monitoring activities, inclusion/exclusion criteria, and study endpoints.
• Collaboration: The study is conducted in collaboration with an internationally recognized regulatory consulting group involved in protocol development and regulatory submissions.
• Company Stage: Preclinical study phase transitioning into first-in-human clinical trials.

Notable Quotes

• "Receiving ethics committee approval is a defining moment in Ocumetics' 18-year journey to revolutionize vision care. With this green light, we are poised to move forward with the first clinical use of the Ocumetics Lens -- a technology designed to provide patients undergoing cataract surgery with the ability to see distant and near objects clearly without the aid of glasses or contact lenses. This marks the historic beginning of a new chapter in ophthalmology." — Dean Burns, CEO
• "We are thrilled to reach this important milestone for Ocumetics. The ethics committee's approval reflects both the strength of the protocol and the readiness of the clinical team. This study represents a major leap forward in innovative intraocular lens development, and we're honoured to be part of it." — Dean Burns, CEO